Devices and methods for reducing the appearance of cellulite

Patent metadata

Field	Value
Publication number	US-10117892-B2
Application number	US-201414473319-A
Country	US
Kind code	B2
Filing date	Aug 29, 2014
Priority date	Aug 29, 2013
Publication date	Nov 6, 2018
Grant date	Nov 6, 2018

Abstract

Methods and devices for use in reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient are provided. The methods include the steps of disrupting fibrous septae located beneath the skin of a cellulitic region and introducing a composition beneath the skin, the composition being effective to reduce or prevent regrowth of the fibrous septae.

First claim

What is claimed is:

1. A composition useful for reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient, the composition comprising:
an injectable gel comprising:
a mixture of at least collagenase I and collagenase II in a mass ratio of 1:1, the mixture having a specific activity of at least about 500 SRC units/mg; and
at least one hyaluronic acid combined with or mixed with the collagenase I and collagenase II, the at least one hyaluronic acid present in an amount effective to provide a physical barrier between tissue planes to discourage regrowth of septal bands disrupted by the collagenase mixture: and
at least one lipolytic agent capable of causing a reduction in the fat stores of adipocytes, wherein the at least one lipolytic agent is selected from the group consisting of phosphatidylcholine, conjugated linoleic acid, deoxycholate, magnolol, and a lipolytic enzyme.

2. The composition of claim 1 , the mixture having specific activity from about 500 SRC units/mg to about 15,000 SRC units/mg.

3. The composition of claim 1 , the mixture having specific activity of at least about 700 SRC units/mg.

4. The composition of claim 1 , the mixture having specific activity of at least about 1000 SRC units/mg.

5. The composition of claim 1 , the mixture having specific activity of at least about 1500 SRC units/mg.

6. The composition of claim 1 , comprising the at least one hyaluronic acid in a concentration of between about 10 mg/mL and 40 mg/mL.

7. The composition of claim 1 , wherein the at least one hyaluronic acid comprises a first and a second hyaluronic acid where the first hyaluronic acid has a higher viscosity than the second hyaluronic acid.

8. The composition of claim 1 , wherein the at least one hyaluronic acid is a crosslinked hyaluronic acid.

9. The composition of claim 8 , wherein the at least one hyaluronic acid is crosslinked with a crosslinker selected from the group consisting of glutaraldehyde (GTA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 1,4-butanediol diglycidyl ether (BDDE), and divinyl sulfone (DVS).

Assignees

• Allergan Inc

Inventors

• Perry Tracy Ann
• Avelar Rui
• Schwab Justin
• Dominguez Zachary
• Kayda Edwin

Classifications

• A61K31/728 Primary

  Hyaluronic acid · CPC title

• A61B17/3421

  Cannulas · CPC title

• A61B2017/320028

  with reciprocating movements · CPC title

• A61Q19/06

  for countering cellulitis · CPC title

• A61K2800/91

  Injection · CPC title